P16INK4a In Oular Surface Squamous Neoplasia | 12183
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

6th International Conference on Vaccines and Immunology

Geneva, Switzerland

3rd European Congress on Virology

Geneva, Switzerland
Google Scholar citation report
Citations : 1600

Journal of Biotechnology & Biomaterials received 1600 citations as per Google Scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

p16INK4a in Oular Surface Squamous Neoplasia

4th World Congress on Biotechnology

Sheeta Chauhan, Seema Sen, Neeta Singh, Anjana Sharma, Bhavna Chawla, Neelam Pushker, Seema Kashyap and Rajvardhan Azad

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.S1.023

Ocular Surface Squamous Neoplasia (OSSN) is the most common tumour of ocular surface and encompasses both conjunctival intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC). p16INK4a is a tumor suppressor protein, Its inactivation by aberrant methylation of CpG islands is frequent in various cancers. Sixty-four cases of OSSN and 15 normal conjunctival controls were included in this study. Immunohistochemistry and Methylation specific PCR was used to evaluate expression of p16INK4a protein and its methylation status. Follow-up data (16 to 36 months) was available in 48 (75%) cases. Loss of p16INK4a immunoexpression was observed in 72% cases (48) and promoter hypermethylation in 53% (34). P16INK4a promoter hypermethylation showed significant association with immunoexpression(P=<0.0001). Hypermethylation of p16INK4a was not however associated significantly with any clinicopathological features or survival. p16INK4a Overexpression was observed in 18 (28%) OSSN and was absent in all control conjunctival tissues. p16INK4a positive cases belonged to younger age group (P=0.03), had higher T stage (P=0.007), larger tumour size (P=0.04) and invasive SCC (P=0.03). Its expression was seen in all the cases with metastasis (6/6) (P= 0.0002) and death (4/4) (P= 0.004). Although in our study disease free survival was worst in p16INK4a positive cases, the difference was not statistical significant (P=0.09). Loss of p16INK4a expression is frequent in OSSN cases and is caused by aberrant DNA methylation. Overexpression of p16INK4a is a useful indictor of aggressive disease and suggests alteration in pRb pathway in this subset of tumors which may play an important role in the pathogenesis and progression of OSSN.